CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.19613922

Available online at: http://www.iajps.com Review Article

MUCOADHESIVE AND GASTRORETENTIVE DRUG DELIVERY SYSTEMS IN CHRONOTHERAPEUTICS: RECENT ADVANCES IN CONTROLLED RELEASE, SITE-SPECIFIC DELIVERY, AND CIRCADIAN-BASED THERAPY

Shubham G. Padol[1], Dr. Vishal R. Rasve[2*], Kavita A. Gaikwad[3], Sneha A. Mane[4], Sapna S. Ghuge[5], Dasrao Patil[6], Sunil S. Bhagat[7]

[1]HOD, Adsul College of Pharmacy, Chas, Ahilyanagar, Maharashtra-414005

[2*]Associate Professor, SAJVPM's, College of Pharmaceutical Sciences and Research Center, Kada, Ashti, Dist.-Beed, Maharashtra-414202

[3,5]Assistant Professor, Shri Sai Institute of Pharmacy and Research, Chatrapati Sambhajinagar Maharashtra 431008

[4]HOD, Sahyadri College of Pharmacy, Methwade, Sangola, Solapur, Maharashtra 413317

[6] Assistant Professor, Bharat Shikshan Sanstha's, Tatyaraoji More College of Pharmacy, Umerga, Dist.- Dharashiv- 413606 Maharashtra

[7]Assistant Professor, Shraddha Institute of Pharmacy, Kondala Zamre, Washim, Maharashtra 444505

Abstract:

Chronotherapeutics has emerged as a promising approach in modern drug delivery, emphasizing the synchronization of drug release with the body's biological rhythms to enhance therapeutic efficacy and minimize adverse effects. Many physiological processes and disease conditions exhibit circadian variations, governed by the Circadian Rhythm, which significantly influence drug pharmacokinetics and pharmacodynamics. Conventional drug delivery systems often fail to address these temporal variations, leading to suboptimal therapeutic outcomes. In this context, advanced drug delivery strategies such as mucoadhesive and gastroretentive systems have gained considerable attention for their ability to prolong gastric residence time, enhance site-specific delivery, and improve bioavailability. The integration of these systems with chronotherapeutic principles enables precise control over both spatial and temporal drug release. Pulsatile drug delivery systems, time-controlled formulations, and stimuli-responsive systems play a crucial role in achieving chronomodulated release profiles that align with disease-specific circadian patterns. Recent advancements in this field include the development of smart polymers, nanotechnology-based gastroretentive systems, floating microspheres, and 3D-printed dosage forms, as well as the application of artificial intelligence for optimizing drug delivery schedules. These innovations have significantly improved the design and performance of chronotherapeutic systems, offering new opportunities for personalized medicine. This review provides a comprehensive overview of mucoadhesive and gastroretentive drug delivery systems in chronotherapeutics, highlighting recent advances in controlled release technologies, site-specific targeting, and circadian-based therapy. It also discusses current challenges, evaluation techniques, and future perspectives, emphasizing the potential of these systems to revolutionize the treatment of diseases with pronounced circadian patterns.

Keywords: *Chronotherapeutics; Circadian rhythm; Mucoadhesive drug delivery; Gastroretentive systems; Pulsatile drug delivery; Controlled release; Site-specific delivery; Smart polymers; Nanotechnology; Chronomodulated release; Floating drug delivery systems; Personalized medicine.*

Corresponding author:
Dr. Vishal R. Rasve,
Associate Professor,
SAJVPM's, College of Pharmaceutical Sciences and Research Center, Kada, Ashti, Dist.-Beed, Maharashtra-414202
Email: vishalrasve@gmail.com

QR CODE

***Please cite this article in press Vishal R. Rasve et al.,* Mucoadhesive And Gastroretentive Drug Delivery Systems In Chronotherapeutics: Recent Advances In Controlled Release, Site-Specific Delivery, And Circadian-Based Therapy.,** *Indo Am. J. P. Sci, 2026; 13(04).*

INTRODUCTION:

Chronotherapeutics is an advanced therapeutic approach that aligns drug delivery with the body's intrinsic biological rhythms to maximize therapeutic efficacy and minimize adverse effects. It is based on the understanding that many physiological processes, including hormone secretion, enzyme activity, gastric motility, and cellular functions, follow predictable time-dependent patterns over a 24-hour cycle. This concept is closely linked to the Circadian Rhythm, which governs various biological functions through an internal timing system. By synchronizing drug administration with these rhythms, chronotherapeutics aims to deliver medications at the most appropriate time, ensuring optimal drug action and improved patient outcomes.

The significance of circadian rhythm in disease management has gained considerable attention due to its profound influence on the onset, severity, and progression of various diseases. Several pathological conditions exhibit distinct time-dependent patterns; for instance, asthma symptoms tend to worsen during the night, cardiovascular events such as myocardial infarction are more frequent in the early morning hours, and rheumatoid arthritis symptoms are typically more severe upon waking. These variations highlight the necessity of timing drug delivery to correspond with disease activity. Failure to consider these biological fluctuations can result in suboptimal therapeutic responses or increased risk of side effects. Therefore, understanding circadian biology is essential for designing drug delivery systems that can effectively match the temporal needs of the body.

Conventional drug delivery systems, including immediate-release and sustained-release formulations, are generally designed to maintain constant plasma drug concentrations without considering the body's biological rhythms. While these systems are effective in many cases, they often fail to address time-dependent variations in drug absorption, metabolism, and target site sensitivity. As a result, they may lead to inadequate drug levels during peak disease activity or excessive drug exposure during periods of low need, thereby increasing the likelihood of adverse effects. Additionally, conventional formulations may exhibit poor site specificity and limited control over drug release kinetics, which further restricts their effectiveness in chronotherapy-based treatments.

To overcome these limitations, specialized drug delivery approaches such as mucoadhesive and gastroretentive systems have been developed. Mucoadhesive drug delivery systems are designed to adhere to the mucosal lining of the gastrointestinal tract, thereby prolonging the residence time of the dosage form and enhancing drug absorption at specific sites. These systems utilize bioadhesive polymers that interact with mucin, allowing for localized and controlled drug release. On the other hand, gastroretentive drug delivery systems (GRDDS) are formulated to remain in the stomach for extended periods, which is particularly beneficial for drugs that have a narrow absorption window in the upper gastrointestinal tract, are unstable in intestinal pH, or require localized action in the stomach. By increasing gastric residence time and improving site-specific delivery, these systems play a crucial role in enhancing bioavailability and therapeutic efficiency.

The integration of mucoadhesive and gastroretentive technologies offers a promising strategy for chronotherapeutic applications. These combined systems enable precise control over both the spatial and temporal aspects of drug delivery, ensuring that the drug is released at the right site and at the optimal time. Such advanced delivery platforms are particularly useful in developing pulsatile and time-controlled release systems that can match circadian patterns of disease.

The present review aims to provide a comprehensive overview of mucoadhesive and gastroretentive drug delivery systems within the context of chronotherapeutics. It focuses on recent advancements in controlled release technologies, site-specific targeting strategies, and circadian-based therapeutic approaches. Furthermore, the review seeks to highlight the potential of these systems in improving treatment outcomes for chronobiology-associated diseases, while also addressing current challenges and future perspectives in this evolving field.

Table 1: Comparison Between Conventional and Chronotherapeutic Drug Delivery Systems

Parameter	Conventional Drug Delivery	Chronotherapeutic Drug Delivery
Drug release pattern	Constant or immediate	Time-dependent / pulsatile
Consideration of circadian rhythm	Not considered	Specifically targeted
Therapeutic efficiency	Moderate	High
Side effects	May be higher	Reduced
Site specificity	Limited	Enhanced
Drug dosing time	Fixed	Optimized according to biological rhythm
Examples	Immediate-release tablets	Pulsatile, gastroretentive systems

BIOLOGICAL BASIS OF CHRONOTHERAPEUTICS

The concept of chronotherapeutics is fundamentally rooted in the biological timing system of the human body, which regulates various physiological and biochemical processes in a rhythmic manner. These rhythms are predominantly governed by the Circadian Rhythm, a natural, endogenous cycle that repeats approximately every 24 hours. Circadian rhythms influence a wide range of bodily functions including sleep–wake cycles, hormone secretion, metabolic activity, gastrointestinal motility, and cardiovascular performance. These time-dependent variations play a crucial role in determining the onset, progression, and severity of many diseases, thereby providing a scientific basis for time-specific drug delivery.

At the core of circadian regulation lies the Biological Clock, primarily located in the suprachiasmatic nucleus (SCN) of the hypothalamus. This master clock synchronizes peripheral clocks present in various organs such as the liver, stomach, heart, and kidneys. It responds to environmental cues, particularly light and darkness, to maintain internal physiological harmony. The biological clock regulates gene expression, enzymatic activity, and cellular functions, thereby influencing pharmacokinetic and pharmacodynamic processes. Disruptions in this clock, such as those caused by irregular lifestyles or disease conditions, can significantly alter drug response and therapeutic outcomes.

Hormonal and physiological parameters also exhibit marked circadian variations, which are highly relevant to chronotherapeutic drug design. For instance, cortisol levels typically peak in the early morning hours, contributing to increased alertness and metabolic activity, while melatonin secretion rises during the الليل, promoting sleep. Similarly, gastric physiology—including gastric pH, enzyme secretion, and gastric emptying rate—varies throughout the day. Gastric acid secretion is often higher at night, which is particularly significant in conditions such as peptic ulcer disease. These rhythmic fluctuations influence drug absorption, stability, and bioavailability, thereby necessitating time-specific delivery systems.

A number of diseases are strongly influenced by circadian rhythms, demonstrating predictable patterns in symptom severity. Asthma, for example, commonly worsens during the night due to increased airway resistance and inflammatory mediator release. Hypertension is characterized by a pronounced early morning surge in blood pressure, which is associated with a higher risk of cardiovascular events such as stroke and myocardial infarction. Rheumatoid arthritis symptoms, including joint pain and stiffness, are typically more severe in the early morning due to nocturnal inflammatory activity. Similarly, peptic ulcer disease often exhibits increased gastric acid secretion at night, leading to nocturnal pain and discomfort. These observations underscore the importance of aligning drug delivery with disease-specific biological rhythms to achieve optimal therapeutic outcomes.

CHRONOPHARMACOLOGY

Chronopharmacology is a specialized branch of pharmacology that studies the influence of biological rhythms on drug action, encompassing both pharmacokinetics and pharmacodynamics. It provides critical insights into how the timing of drug administration affects drug absorption, distribution, metabolism, and excretion, as well as the intensity and duration of pharmacological effects.

Chronokinetics refers to the time-dependent variations in pharmacokinetic parameters (ADME). Absorption of drugs can vary depending on gastrointestinal conditions such as pH, motility, and blood flow, all of which are influenced by circadian rhythms. Drug distribution may also fluctuate due to variations in plasma protein binding and tissue permeability. Hepatic metabolism, governed by enzyme activity such as cytochrome P450, exhibits diurnal variation, leading to differences in drug biotransformation rates. Similarly, renal excretion changes with circadian patterns in renal blood flow and glomerular filtration rate. These variations can significantly affect plasma drug concentrations and therapeutic efficacy.

Chronodynamics, on the other hand, deals with the time-dependent variation in drug response at the target site. This includes fluctuations in receptor sensitivity, signal transduction pathways, and cellular responsiveness. For example, certain receptors may exhibit higher sensitivity during specific times of the day, resulting in enhanced or diminished drug effects. Understanding these variations is essential for optimizing drug dosing schedules and minimizing adverse effects.

Time-dependent drug response is a key principle of chronopharmacology, emphasizing that the same dose of a drug may produce different therapeutic outcomes depending on the time of administration. This has led to the development of chronotherapeutic drug delivery systems that are designed to release drugs in a pulsatile or controlled manner, synchronized with the body's biological rhythms. Such systems are particularly beneficial in managing diseases with predictable circadian patterns.

Several drugs have been identified as requiring time-specific delivery to achieve maximum therapeutic benefit. For instance, antihypertensive drugs are often more effective when administered in the early morning to counteract the morning surge in blood pressure. Anti-asthmatic medications are typically administered in the evening to prevent nocturnal exacerbations. Nonsteroidal anti-inflammatory drugs (NSAIDs) used in arthritis are more beneficial when timed to address early morning symptoms. Proton pump inhibitors and H2 receptor antagonists are often administered at night to suppress nocturnal gastric acid secretion in peptic ulcer disease. These examples highlight the importance of integrating chronopharmacological principles into drug delivery system design.

Table 2: Circadian Influence on Diseases and Chronotherapeutic Approach

Disease	Circadian Pattern	Physiological Basis	Chronotherapeutic Strategy
Asthma	Night-time worsening	Increased airway resistance	Evening dosing / pulsatile release
Hypertension	Morning surge	Increased sympathetic activity	Early morning drug release
Arthritis	Morning stiffness	ночurnal inflammation	Bedtime dosing
Peptic ulcer	Night-time acid secretion	Increased gastric acid output	Night-time drug delivery





Figure 1: Schematic representation of the circadian rhythm and its influence on physiological functions and disease symptoms. Hormonal variations such as cortisol and melatonin levels regulate biological processes over a 24-hour cycle, contributing to time-dependent disease patterns including nocturnal asthma, morning hypertension, and early morning arthritis symptoms.

MUCOADHESIVE DRUG DELIVERY SYSTEMS

Mucoadhesive drug delivery systems represent an advanced and highly effective approach for enhancing the bioavailability and therapeutic performance of drugs, particularly those administered via the gastrointestinal tract. These systems are designed to adhere to the mucus layer covering biological membranes, thereby prolonging the residence time of the dosage form at the site of absorption. By maintaining close and extended contact with the mucosal surface, mucoadhesive systems facilitate improved drug absorption, reduced dosing frequency, and enhanced site-specific delivery. This approach is especially beneficial for drugs with poor bioavailability, narrow absorption windows, or those intended for localized action within the gastrointestinal tract. In the context of chronotherapeutics, mucoadhesive systems provide an additional advantage by enabling controlled and time-dependent drug release aligned with circadian variations.

Concept of Mucoadhesion

Mucoadhesion refers to the phenomenon by which a material adheres to the mucosal surfaces of the body through physicochemical interactions. It involves a two-step process: the initial contact between the dosage form and the mucosal surface, followed by the consolidation stage, where adhesive interactions are established and strengthened. The significance of mucoadhesion lies in its ability to increase the residence time of the drug delivery system at the site of application, thereby enhancing drug absorption and therapeutic efficacy.

The mechanism of mucoadhesion is explained through several well-established theories. The wetting theory describes the ability of a liquid or semi-solid formulation to spread over the mucosal surface, emphasizing the importance of surface energy and contact angle. The diffusion theory involves the interpenetration of polymer chains with mucin glycoproteins, leading to the formation of a semi-permanent adhesive bond. The electronic theory is based on the transfer of electrons between the mucoadhesive material and the mucus layer, resulting in the formation of electrical double layers that promote adhesion. The fracture theory focuses on the mechanical strength of the adhesive bond and defines mucoadhesion in terms of the force required to separate the dosage form from the mucosal surface. Collectively, these theories provide a comprehensive understanding of the complex interactions involved in mucoadhesion.



Figure 2: Mechanism of mucoadhesion showing the stages of contact and consolidation between mucoadhesive polymers and the mucus layer. Various theories including wetting, diffusion, electronic, and fracture theories explain the interactions responsible for adhesion.

Mucoadhesive Polymers

Polymers play a crucial role in the design and performance of mucoadhesive drug delivery systems. They are responsible for providing the necessary adhesive properties, controlling drug release, and ensuring biocompatibility. Mucoadhesive polymers are broadly classified into natural and synthetic categories based on their origin.

Natural polymers such as chitosan, sodium alginate, and guar gum are widely used due to their biocompatibility, biodegradability, and low toxicity. Chitosan, a cationic polymer derived from chitin, exhibits excellent mucoadhesive properties due to its ability to form electrostatic interactions with negatively charged mucin. Sodium alginate, obtained from brown seaweed, forms gels in the presence of divalent cations and provides controlled drug release. Guar gum, a plant-derived polysaccharide, is known for its high swelling capacity and viscosity, which contribute to prolonged retention and sustained drug release.

Synthetic polymers, on the other hand, offer greater control over physicochemical properties and reproducibility. Carbopol (polyacrylic acid) is one of the most widely used mucoadhesive polymers due to its high swelling capacity and strong hydrogen bonding with mucin. Hydroxypropyl

methylcellulose (HPMC) is commonly employed for its film-forming ability and controlled release characteristics. Polycarbophil is another important polymer that exhibits strong bioadhesive properties due to its high density of carboxyl groups, which facilitate hydrogen bonding with the mucus layer. The selection of an appropriate polymer or combination of polymers is critical for achieving the desired mucoadhesive strength and drug release profile.

Evaluation Parameters of Mucoadhesive Systems

The performance of mucoadhesive drug delivery systems is evaluated using a range of physicochemical and biological parameters to ensure their effectiveness and reliability. One of the key parameters is mucoadhesive strength, which measures the force required to detach the dosage form from the mucosal surface. This parameter is critical in determining the ability of the system to remain attached for a sufficient duration.

The swelling index is another important parameter that reflects the ability of the polymer to absorb water and expand. Swelling plays a significant role in facilitating intimate contact between the dosage form and the mucosal surface, thereby enhancing adhesion and controlling drug release. However, excessive swelling may lead to premature detachment or discomfort.

Residence time refers to the duration for which the dosage form remains adhered to the mucosal surface. A longer residence time is generally associated with improved drug absorption and therapeutic efficacy. This parameter is influenced by factors such as polymer composition, mucosal turnover, and physiological conditions.

In addition to in vitro evaluation methods, in vivo studies are essential for assessing the actual performance of mucoadhesive systems under physiological conditions. In vitro tests typically involve the use of simulated mucosal surfaces and controlled environments, while in vivo studies may include imaging techniques and pharmacokinetic analysis to evaluate adhesion, residence time, and drug absorption in living systems. Together, these evaluation parameters provide a comprehensive assessment of the effectiveness of mucoadhesive drug delivery systems.

Table 3: Common Mucoadhesive Polymers and Their Characteristics

Polymer	Type	Key Properties	Advantages	Limitations
Chitosan	Natural	Cationic, biodegradable	Excellent adhesion, biocompatible	pH-dependent solubility
Sodium Alginate	Natural	Gel-forming	Controlled release	Weak mechanical strength
Guar Gum	Natural	High swelling	Sustained release	Variable viscosity
Carbopol	Synthetic	High swelling, acidic	Strong mucoadhesion	Irritation at high conc.
HPMC	Synthetic	Hydrophilic, film-forming	नियंत्रित release	Moderate adhesion
Polycarbophil	Synthetic	High carboxyl content	Strong adhesion	Expensive

Integration of Mucoadhesive and Gastroretentive Drug Delivery Systems

The integration of mucoadhesive and gastroretentive drug delivery systems represents a rational and synergistic strategy to enhance the performance of oral drug delivery. Individually, gastroretentive systems are designed to prolong the residence time of dosage forms in the stomach, while mucoadhesive systems ensure firm attachment to the gastric mucosa. When combined, these approaches provide both prolonged gastric retention and intimate mucosal contact, thereby significantly improving drug absorption and therapeutic efficacy. This dual-function strategy is particularly valuable in chronotherapeutic applications, where both spatial (site-specific) and temporal (time-controlled) delivery are critical.

In such integrated systems, the dosage form is engineered to remain in the gastric region through mechanisms such as buoyancy, swelling, or expansion, while simultaneously adhering to the mucosal lining via bioadhesive polymers. This combined effect minimizes premature gastric emptying and reduces variability caused by physiological factors such as gastric motility and food intake. As a result, the drug is retained at the optimal absorption site for a prolonged duration, enabling controlled and predictable drug release profiles.



Figure 3: Approaches of GRDDS

One of the major advantages of this integrated approach is the enhanced bioavailability of drugs that exhibit a narrow absorption window in the upper gastrointestinal tract. Many drugs are primarily absorbed in the stomach or proximal small intestine, and rapid transit through these regions can lead to incomplete absorption and reduced therapeutic effect. By extending gastric residence time and maintaining close contact with the absorption surface, mucoadhesive gastroretentive systems ensure more efficient drug uptake. This is particularly beneficial for drugs such as riboflavin, levodopa, and certain antibiotics, which require localized absorption for optimal efficacy.

In addition, this approach significantly improves the delivery of poorly soluble drugs. Drugs with low aqueous solubility often face challenges in dissolution and absorption, especially in the varying pH conditions of the gastrointestinal tract. By retaining the drug in the stomach, where the environment may be more favorable for dissolution, and by providing a controlled release mechanism, integrated systems enhance drug solubilization and absorption. Furthermore, the presence of hydrophilic polymers in mucoadhesive formulations promotes swelling and gel formation, which aids in sustained drug release and improved dissolution kinetics.

Dual-function systems have been successfully developed in various forms, including floating-mucoadhesive tablets, bioadhesive microspheres, and expandable hydrogels with adhesive properties. Floating-mucoadhesive tablets combine low-density characteristics with strong adhesion to gastric mucosa, ensuring both buoyancy and retention. Bioadhesive microspheres provide a multiparticulate approach, offering uniform distribution in the stomach and reduced risk of dose dumping. Expandable systems, which swell upon contact with gastric fluids, can also be functionalized with mucoadhesive polymers to enhance retention and site specificity.

Table 4: Integrated Mucoadhesive–Gastroretentive Systems and Their Advantages

System Type	Mechanism	Key Features	Applications
Floating mucoadhesive tablets	Buoyancy + adhesion	Prolonged gastric retention	Narrow absorption window drugs
Bioadhesive microspheres	Adhesion + multiparticulate	Uniform distribution, reduced dose dumping	Controlled release formulations
Expandable bioadhesive systems	Swelling + adhesion	Prevent gastric emptying	Sustained drug delivery
Mucoadhesive hydrogels	Gel formation + adhesion	Enhanced contact with mucosa	Local gastric therapy

Overall, the integration of mucoadhesive and gastroretentive systems offers a highly efficient platform for improving oral drug delivery, particularly for drugs requiring site-specific and time-controlled release. This approach aligns well with the principles of chronotherapeutics by enabling precise control over drug release kinetics and ensuring that the drug is available at the right place and at the right time.

CONTROLLED RELEASE STRATEGIES IN CHRONOTHERAPEUTICS

Controlled release drug delivery systems are designed to deliver drugs at a predetermined rate, for a specified period, and at a targeted site to achieve optimal therapeutic outcomes. In chronotherapeutics, these systems are particularly important because they enable synchronization of drug release with the body's biological rhythms, thereby improving efficacy and minimizing adverse effects.

A clear distinction exists between sustained release and controlled release systems. Sustained release formulations are intended to prolong drug release over an extended period, maintaining relatively constant plasma drug concentrations. However, they do not specifically account for the timing of disease symptoms. In contrast, controlled release systems are engineered to deliver drugs according to a predefined release pattern, which may include time-dependent or site-specific delivery. In chronotherapy, controlled release systems are preferred because they can be tailored to match circadian variations in disease activity.

Among the various controlled release approaches, pulsatile drug delivery systems hold particular significance. These systems are characterized by a lag phase followed by a rapid and complete release of the drug. This release pattern is highly beneficial for diseases that exhibit circadian rhythms, where symptoms occur or intensify at specific times of the day. For example, a pulsatile system can be administered at bedtime but programmed to release the drug in the early morning hours when symptoms of hypertension or arthritis are most severe. Such systems enhance therapeutic precision while reducing unnecessary drug exposure during periods of low disease activity.

Time-controlled drug delivery systems are a key component of pulsatile release technology. Lag time systems are designed to delay drug release for a specific period after administration, allowing synchronization with the onset of symptoms. These systems often utilize coatings or barrier layers that dissolve or rupture after a predetermined time. Sigmoidal release systems, on the other hand, exhibit a characteristic "S-shaped" release profile, where an initial lag phase is followed by a rapid increase in drug release and eventually a plateau. This type of release is particularly useful for achieving a sharp increase in drug concentration at the desired time.

Polymer-based release modulation plays a central role in the development of controlled and pulsatile systems. Hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC) and polyethylene oxide (PEO) are widely used to regulate drug release through swelling and gel formation. PH-sensitive polymers enable site-specific release by responding to changes in gastrointestinal pH, while biodegradable polymers allow for gradual drug release through polymer degradation. By carefully selecting and combining polymers, it is possible to design drug delivery systems with precise control over release kinetics, making them highly suitable for chronotherapeutic applications.

Table 5: Controlled Release Systems in Chronotherapeutics

System Type	Release Pattern	Mechanism	Application
Sustained release	Continuous	Diffusion/erosion	General therapy
Controlled release	Predefined	Polymer modulation	Chronotherapy
Pulsatile systems	Lag + burst	Coating rupture/osmotic	Asthma, hypertension
Sigmoidal systems	S-shaped	Polymer swelling	Time-specific delivery
Lag-time systems	Delayed release	Barrier coating	Early morning symptoms

SITE-SPECIFIC DRUG DELIVERY

Site-specific drug delivery systems are designed to deliver drugs directly to a targeted region within the body, thereby maximizing local drug concentration and minimizing systemic side effects. In the context of gastroretentive and mucoadhesive systems, site-specific delivery is primarily focused on the stomach and upper gastrointestinal tract, where many drugs exhibit optimal absorption or localized therapeutic action.

Targeting the stomach and upper gastrointestinal tract is particularly advantageous for drugs that are either unstable in the intestinal environment or require localized action in the gastric region. Gastroretentive systems ensure prolonged retention in the stomach, while mucoadhesive systems facilitate close contact with the gastric mucosa. Together, these approaches enable efficient and localized drug delivery, improving therapeutic outcomes.

Site-specific delivery plays a crucial role in the management of several gastric disorders. In infections caused by Helicobacter pylori, localized delivery of antibiotics in the stomach enhances eradication rates by maintaining effective drug concentrations at the site of infection. In gastric cancer, targeted delivery of anticancer agents to the stomach can improve drug efficacy while reducing systemic toxicity. Similarly, in peptic ulcer disease, site-specific delivery of proton pump inhibitors or mucosal protective agents helps in reducing gastric acid secretion and promoting ulcer healing.

Bioadhesion is a key factor in achieving effective site-specific delivery. Mucoadhesive polymers enable the dosage form to adhere to the gastric mucosa, thereby prolonging residence time and ensuring localized drug release. This not only enhances drug absorption but also reduces drug loss due to gastric emptying. In chronotherapeutics, the combination of site-specific and time-controlled delivery allows drugs to be released at the right location and at the most appropriate time, aligning with the circadian pattern of disease activity.

Table 6: Site-Specific Drug Delivery in Gastric Disorders

Disease	Target Site	Drug Strategy	Benefit
H. pylori infection	Stomach	Local antibiotic delivery	Increased eradication
Peptic ulcer	Gastric mucosa	Acid suppression therapy	Faster healing
Gastric cancer	Stomach lining	Targeted chemotherapy	Reduced toxicity

CHRONOTHERAPEUTIC DRUG DELIVERY SYSTEMS

Chronotherapeutic drug delivery systems are advanced pharmaceutical formulations specifically designed to synchronize drug release with the body's biological rhythms, particularly the Circadian Rhythm. These systems aim to deliver drugs at the most appropriate time of the day when disease symptoms are most pronounced, thereby maximizing therapeutic efficacy and minimizing adverse effects. Unlike conventional dosage forms that provide continuous or immediate drug release, chronotherapeutic systems are engineered to achieve time-dependent, pulsatile, or programmed drug release profiles.

The development of such systems is based on the understanding that many diseases exhibit predictable circadian patterns. Therefore, aligning drug release with these patterns can significantly enhance treatment outcomes. Chronotherapeutic systems are particularly useful in the management of conditions such as asthma, hypertension, arthritis, and gastric disorders, where symptom severity varies over a 24-hour cycle.

PULSATILE DRUG DELIVERY SYSTEMS

Pulsatile drug delivery systems are a key component of chronotherapeutics and are characterized by a distinct release profile consisting of a lag phase followed by a rapid and complete release of the drug. This approach is designed to mimic the body's natural rhythms and provide drug release at the time when it is most needed. The importance of pulsatile systems lies in their ability to deliver drugs in a time-controlled manner, thereby improving therapeutic precision and reducing unnecessary drug exposure.

These systems are especially beneficial for diseases that exhibit circadian variation, where symptoms occur or worsen at specific times of the day. For example, a pulsatile formulation administered at bedtime can be programmed to release the drug in the early morning hours to counteract the morning surge in blood pressure or early morning stiffness in arthritis.

Pulsatile drug delivery systems can be broadly classified into time-controlled systems and stimuli-responsive systems. Time-controlled systems rely on internal formulation parameters to achieve a predetermined lag time before drug release. These systems often utilize coatings, barrier layers, or erodible polymers that dissolve or rupture after a specific duration. In contrast, stimuli-responsive systems release drugs in response to external or internal triggers such as pH changes, temperature variations, enzymatic activity, or osmotic pressure. These systems offer greater adaptability and precision, as drug release is triggered by physiological conditions rather than a fixed time schedule.

TECHNOLOGIES USED IN PULSATILE DRUG DELIVERY

A variety of advanced technologies have been developed to achieve pulsatile drug release, each based on different mechanisms and design principles. Among these, osmotic systems are widely used due to their ability to provide precise and reproducible drug release profiles. These systems utilize osmotic pressure to control drug release, where water enters the dosage form through a semi-permeable membrane, generating pressure that eventually leads to the rupture of a coating or the expulsion of the drug after a defined lag time.

Rupturable coating systems are another important category, where the drug core is surrounded by a polymeric coating that breaks or ruptures after a certain period due to internal pressure generated by swelling agents or gas formation. This mechanism ensures a sharp and rapid release of the drug following the lag phase, making it highly suitable for chronotherapeutic applications.

Floating pulsatile systems combine the principles of gastroretention and pulsatile release. These systems remain buoyant in the gastric fluid and release the drug after a predetermined lag time, ensuring that the drug is delivered at the desired site and time. This dual functionality is particularly advantageous for drugs that require prolonged gastric residence and time-specific release.

Multiparticulate systems, such as pellets, beads, and microspheres, offer an alternative approach to pulsatile drug delivery. These systems consist of multiple small units, each capable of releasing the drug at different time intervals. This provides greater flexibility in designing complex release profiles and reduces the risk of dose dumping. Additionally, multiparticulate systems ensure uniform distribution in the gastrointestinal tract, leading to more consistent drug absorption.

Table 7: Pulsatile Drug Delivery Systems and Technologies

System Type	Mechanism	Key Features	Advantages
Time-controlled systems	Predefined lag time	Polymer coating/erosion	Predictable release
Stimuli-responsive systems	Trigger-based release	pH, enzyme, temperature sensitive	High precision
Osmotic systems	Osmotic pressure	Controlled lag and release	Reproducible performance
Rupturable coating systems	Pressure-induced rupture	Rapid drug release	Suitable for pulsatile delivery
Floating pulsatile systems	Buoyancy + lag time	Gastric retention	Site-specific + timed release
Multiparticulate systems	Multiple units	Distributed release	Reduced dose dumping

RECENT ADVANCES IN CHRONOTHERAPEUTIC DRUG DELIVERY SYSTEMS

Recent years have witnessed significant progress in the development of advanced drug delivery systems that integrate chronotherapeutic principles with innovative materials and technologies. These advancements aim to achieve precise control over the timing, location, and rate of drug release, thereby enhancing therapeutic outcomes and patient compliance. The convergence of polymer science, nanotechnology, digital health, and artificial intelligence has opened new avenues for designing sophisticated systems capable of responding to physiological cues and circadian variations.

Smart Polymers (pH- and Enzyme-Responsive Systems)

Smart polymers, also known as stimuli-responsive polymers, have emerged as a cornerstone in modern chronotherapeutic drug delivery. These polymers possess the unique ability to alter their physicochemical properties in response to environmental triggers such as pH, temperature, enzymes, or ionic strength. In the gastrointestinal tract, pH-sensitive polymers can be engineered to remain stable in acidic gastric conditions and release the drug upon exposure to higher intestinal pH, or vice versa depending on therapeutic requirements. Enzyme-responsive polymers, on the other hand, are designed to degrade in the presence of specific enzymes, enabling site-specific and time-dependent drug release.

These polymers are particularly advantageous in chronotherapy because they can be programmed to release drugs in response to physiological changes that follow the Circadian Rhythm. For instance, enzyme activity and pH fluctuations in the gastrointestinal tract vary throughout the day, allowing smart polymers to synchronize drug release with these biological patterns. This adaptability enhances therapeutic precision and reduces the risk of dose-related side effects.

Nanotechnology-Based Gastroretentive Drug Delivery Systems

Nanotechnology has revolutionized drug delivery by enabling the design of nanoscale carriers with enhanced surface area, improved drug loading capacity, and targeted delivery capabilities. In gastroretentive systems, nanoparticles can be engineered to exhibit mucoadhesive, floating, or swelling properties, thereby prolonging gastric residence time and improving drug absorption.

Nanocarriers such as polymeric nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers are widely explored for chronotherapeutic applications. These systems can be functionalized with ligands or polymers to achieve site-specific targeting and controlled drug release. Additionally, their small size allows for better penetration into biological membranes, enhancing bioavailability. The integration of nanotechnology with

gastroretentive systems provides a powerful platform for delivering drugs in a controlled and time-dependent manner.



Figure 4: Illustration of an integrated mucoadhesive and gastroretentive drug delivery system showing prolonged gastric retention through buoyancy and adhesion to the gastric mucosa for enhanced bioavailability.

Floating Microspheres and Nanoparticles

Floating microspheres and nanoparticles represent an advanced class of gastroretentive systems designed to remain buoyant in the gastric environment while providing sustained or pulsatile drug release. These systems are typically composed of low-density polymers that enable them to float on gastric fluids, thereby prolonging gastric residence time.

Floating microspheres offer the advantage of multiparticulate distribution, which ensures uniform drug release and reduces the risk of dose dumping. When combined with mucoadhesive properties, these systems can adhere to the gastric mucosa, further enhancing retention and site-specific delivery. Floating nanoparticles, due to their smaller size, provide improved surface interaction and enhanced drug absorption. These systems are particularly useful in chronotherapeutics for delivering drugs at specific times corresponding to circadian variations in disease activity.

3D Printing in Drug Delivery

Three-dimensional (3D) printing has emerged as a transformative technology in pharmaceutical manufacturing, enabling the fabrication of personalized and complex drug delivery systems. This technology allows precise control over the geometry, composition, and internal structure of dosage forms, making it possible to design systems with tailored drug release profiles.

In chronotherapeutics, 3D printing can be used to create multi-layered or compartmentalized dosage forms that release drugs at different time intervals. For example, a single tablet can be designed with distinct layers that dissolve sequentially, providing pulsatile or time-controlled drug release. Additionally, 3D printing facilitates the development of patient-specific formulations based on individual circadian rhythms, disease conditions, and pharmacokinetic profiles. This approach aligns with the concept of personalized medicine and enhances therapeutic outcomes.

AI-Based Chronotherapy Optimization

Artificial intelligence (AI) is playing an increasingly important role in optimizing chronotherapeutic drug delivery. AI algorithms can analyze large datasets related to patient physiology, disease patterns, and drug pharmacokinetics to determine the optimal timing and dosing of medications. Machine learning models can predict circadian variations in drug response and help design drug delivery systems that align with these patterns.

AI can also assist in the development of advanced formulations by simulating drug release profiles and optimizing formulation parameters. Furthermore, integration with wearable devices and digital health technologies enables real-time monitoring of patient conditions, allowing dynamic adjustment of drug delivery schedules. This data-driven approach enhances the precision and effectiveness of chronotherapy.





Figure 5: Recent advances in chronotherapeutic drug delivery including smart polymers, nanotechnology-based systems, floating microspheres, 3D-printed dosage forms, and AI-driven personalized medicine approaches.

Chronomodulated Release Coatings

Chronomodulated release coatings are specifically designed to control the timing of drug release by introducing a predetermined lag phase followed by rapid drug release. These coatings are typically composed of polymers that undergo time-dependent swelling, erosion, or rupture. By adjusting the thickness and composition of the coating, it is possible to precisely control the lag time and release profile. Such coatings are widely used in pulsatile drug delivery systems to synchronize drug release with circadian rhythms. For instance, a drug administered at bedtime can be coated in such a way that it is released in the early morning hours when symptoms are most severe. Chronomodulated coatings are particularly useful in the treatment of diseases such as hypertension, asthma, and arthritis, where symptom severity follows a predictable daily pattern.

Table 8: Recent Advances in Chronotherapeutic Drug Delivery

Technology	Mechanism	Key Advantages	Applications
Smart polymers	Stimuli-responsive (pH, enzyme)	Site-specific, adaptive release	GI-targeted delivery
Nanotechnology-based GRDDS	Nano-carriers with targeting ability	Enhanced bioavailability	Controlled release systems
Floating microspheres/nanoparticles	Buoyancy + adhesion	Prolonged gastric retention	Chronotherapy
3D printing	Layered/programmable systems	Personalized medicine	Pulsatile delivery
AI-based systems	Data-driven optimization	Precision dosing	Chronotherapy planning
Chronomodulated coatings	Time-dependent lag phase	Accurate timing of release	Circadian diseases

APPLICATIONS IN DISEASE MANAGEMENT

Chronotherapeutic drug delivery systems have gained considerable importance in the management of various diseases that exhibit circadian patterns in their onset and severity. By aligning drug release with biological rhythms, these systems enhance therapeutic outcomes, improve patient compliance, and reduce adverse effects. The integration of mucoadhesive and gastroretentive technologies further strengthens their applicability by ensuring prolonged residence and site-specific delivery.

In cardiovascular disorders such as hypertension, circadian variation plays a crucial role, with blood pressure typically rising sharply in the early morning hours a phenomenon often referred to as the "morning surge." This increase is associated with a higher risk of myocardial infarction and stroke. Chronotherapeutic formulations are

designed to release antihypertensive drugs during these critical hours, thereby providing optimal protection. Similarly, in asthma, airway resistance and inflammatory responses tend to worsen during the night, making evening or delayed-release formulations more effective in controlling nocturnal symptoms.

In the management of rheumatoid arthritis, patients commonly experience severe joint pain and stiffness in the early morning due to nocturnal inflammatory activity. Chronotherapeutic systems that release anti-inflammatory drugs after a programmed lag time can significantly reduce morning discomfort and improve mobility. In gastrointestinal disorders such as peptic ulcer disease, gastric acid secretion is typically higher during the night. Gastroretentive and mucoadhesive systems enable localized and sustained drug delivery in the stomach, enhancing ulcer healing and symptom control.

Chronotherapy also plays a significant role in diabetes management, where insulin sensitivity and glucose metabolism vary throughout the day. Time-specific delivery of antidiabetic drugs can improve glycemic control and reduce the risk of hypoglycemia. In cancer therapy, circadian rhythms influence cell cycle progression, DNA repair mechanisms, and drug metabolism. Chronomodulated chemotherapy aims to deliver anticancer agents at times when tumor cells are most vulnerable and healthy cells are least sensitive, thereby improving therapeutic efficacy and minimizing toxicity.

Neurological disorders, including epilepsy and depression, also exhibit circadian patterns in symptom occurrence and severity. Chronotherapeutic drug delivery systems can be tailored to provide drug release at times when symptoms are most likely to occur, ensuring better disease management. Overall, the application of chronotherapy across a wide range of diseases highlights its potential as a powerful tool in modern medicine.

Table 9: Applications of Chronotherapeutics in Disease Management

Disease	Circadian Pattern	Chronotherapeutic Approach	Benefit
Hypertension	Morning surge	Delayed-release antihypertensives	Reduced CV risk
Asthma	Night worsening	Evening dosing / pulsatile release	Better symptom control
Arthritis	Morning stiffness	Bedtime dosing	Reduced pain
Peptic ulcer	Night acid secretion	Gastroretentive systems	Enhanced healing
Cancer	Cell cycle variation	Chronomodulated chemotherapy	Reduced toxicity

EVALUATION AND CHARACTERIZATION TECHNIQUES

The development of chronotherapeutic drug delivery systems requires comprehensive evaluation and characterization to ensure their performance, safety, and reliability. Both in vitro and in vivo methods are employed to assess various parameters related to drug release, gastric retention, mucoadhesion, and pharmacokinetics.

In vitro evaluation techniques are essential for preliminary assessment of formulation performance. Dissolution studies are conducted to evaluate drug release profiles, particularly for pulsatile systems where a defined lag phase followed by rapid release is expected. Floating lag time and total floating duration are measured for gastroretentive systems to determine their buoyancy characteristics. Swelling studies and mucoadhesive strength tests are performed to assess the interaction between the formulation and the mucosal surface. Additionally, physicochemical properties such as hardness, friability, and drug content uniformity are evaluated to ensure formulation stability and consistency.

In vivo evaluation provides a more accurate assessment of the formulation under physiological conditions. Techniques such as gamma scintigraphy and X-ray imaging are used to track the position and movement of the dosage form within the gastrointestinal tract, thereby confirming gastric retention and site-specific delivery. Pharmacokinetic studies are conducted to evaluate parameters such as peak plasma concentration (C_max), time to reach peak concentration (T_max), and area under the curve (AUC), which provides insights into drug absorption and bioavailability.

Advanced modeling and simulation techniques are also employed to predict drug release behavior and optimize formulation parameters. These approaches help in understanding the relationship between formulation design and therapeutic performance, thereby facilitating the development of efficient chronotherapeutic systems.

CONCLUSION:

Chronotherapeutic drug delivery systems represent a significant advancement in pharmaceutical science, offering a strategic approach to align drug

administration with the body's biological rhythms. The integration of mucoadhesive and gastroretentive systems provides enhanced control over drug release, ensuring both site-specific and time-dependent delivery.

By addressing the limitations of conventional drug delivery systems and leveraging recent technological advancements, chronotherapeutic approaches have the potential to improve therapeutic efficacy, reduce side effects, and enhance patient compliance. Although challenges remain in terms of formulation complexity and variability in biological rhythms, ongoing research and innovation are expected to overcome these barriers.

In conclusion, the combination of chronotherapeutics with advanced drug delivery technologies represents a promising direction for the future of precision medicine, offering tailored treatment strategies that align with the dynamic nature of human physiology.

CONFLICT OF INTESTS:
None

REFERENCES:

1. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. *Adv Drug Deliv Rev*. 2007;59(9–10):828–51.
2. Lemmer B. Chronopharmacology: cellular and biochemical interactions. *Ann Rev Pharmacol Toxicol*. 2005;45:593–628.
3. Youan BB. Chronopharmaceutical drug delivery systems: hype or future of pharmacotherapy? *Adv Drug Deliv Rev*. 2010;62(9–10):898–903.
4. Maroni A, Zema L, Del Curto MD, Loreti G, Gazzaniga A. Oral pulsatile delivery: rationale and chronopharmaceutical formulations. *Int J Pharm*. 2010;398(1–2):1–8.
5. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery. *J Control Release*. 2000;63(3):235–59.
6. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. *Expert Opin Drug Deliv*. 2006;3(2):217–33.
7. Deshpande AA, Rhodes CT, Shah NH, Malick W. Controlled-release drug delivery systems for prolonged gastric residence. *Drug Dev Ind Pharm*. 1996;22(6):531–9.
8. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. *Macromol Biosci*. 2011;11(6):748–64.
9. Smart JD. The basics and underlying mechanisms of mucoadhesion. *Adv Drug Deliv Rev*. 2005;57(11):1556–68.
10. Lehr CM. Lectin-mediated drug delivery: the second generation of bioadhesives. *J Control Release*. 2000;65(1–2):19–29.
11. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. *Eur J Pharm Biopharm*. 2009;71(3):505–18.
12. Peppas NA, Sahlin JJ. Hydrogels as mucoadhesive and bioadhesive materials. *Biomaterials*. 1996;17(16):1553–61.
13. Hoffman AS. Hydrogels for biomedical applications. *Adv Drug Deliv Rev*. 2012;64:18–23.
14. Vyas SP, Khar RK. Targeted and controlled drug delivery: novel carrier systems. CBS Publishers; 2002.
15. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. *J Control Release*. 2009;134(2):74–80.
16. Lin SY, Kawashima Y. Current status and approaches to developing press-coated chronodelivery drug systems. *J Control Release*. 2012;157(3):331–53.
17. Gazzaniga A, Busetti C, Moro L, Crimella T, Sangalli ME. Time-dependent oral delivery systems for colon targeting. *Int J Pharm*. 1995;119(1):37–44.
18. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. *Adv Drug Deliv Rev*. 2001;53(3):321–39.
19. Langer R. Drug delivery and targeting. *Nature*. 1998;392:5–10.
20. Rasve VR, Paithankar VV, Shirsat MK, Dhobale AV. Evaluation of antiulcer activity of *Aconitum heterophyllum* on experimental animals. World J Pharm Pharm Sci. 2018;7(2):819–839.
21. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev*. 2012;64:302–15.
22. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. *World J Pharmacol*. 2013;2(2):47–64.
23. Bansal S, Beg S, Asthana A, Garg B, Asthana GS. Chronopharmacology and chronotherapeutics: an overview. *Int J Pharm Sci Rev Res*. 2014;27(2):1–9.
24. Kaur G, Paliwal S. Chronotherapeutics: a novel approach for drug delivery. *Int J Drug Dev Res*. 2013;5(1):1–10.
25. Chien YW. Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 1992.
26. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review. *J Drug Deliv*. 2011;2011:1–9.

27. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility. *J Control Release*. 1996;39(2–3):231–7.
28. Siepmann J, Peppas NA. Modeling of drug release from delivery systems. *Adv Drug Deliv Rev*. 2012;64:163–74.
29. Ritschel WA, Forusz H. Chronopharmacology: a review of drugs studied. *Methods Find Exp Clin Pharmacol*. 1994;16(1):57–75.
30. Lemmer B. The clinical relevance of chronopharmacology in therapeutics. *Pharmacol Res*. 1996;33(2):107–15.
31. Youan BB. Chronotherapeutic drug delivery systems: revisiting the chronopharmaceutical concept. *J Control Release*. 2004;98(3):337–53.
32. Hermida RC, Ayala DE, Smolensky MH, Portaluppi F. Chronotherapy with conventional blood pressure medications improves management of hypertension. *Hypertension*. 2011;57(3):e3–e4.
33. Portaluppi F, Smolensky MH. Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. *Chronobiol Int*. 2010;27(8):1652–67.
34. Reinberg A, Smolensky MH. Biological rhythms and medicine. *Cell Mol Life Sci*. 2003;60(5):973–99.
35. Labrecque G, Bélanger PM. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. *Pharmacol Ther*. 1991;52(1):95–107.
36. Bruguerolle B. Chronopharmacokinetics: current status. *Clin Pharmacokinet*. 1998;35(2):83–94.
37. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Comparative evaluation of antidiabetic activity of ethanolic leaves extract of *Clematis triloba* and its SMEDDS formulation in streptozotocin-induced diabetic rats. J Popul Ther Clin Pharmacol. 2022; 29(4):959–971. doi:10.53555/jptcp.v29i04.2360.
38. Ohdo S. Chronotherapeutic strategy: rhythm monitoring, manipulation and disruption. *Adv Drug Deliv Rev*. 2010;62(9–10):859–75.
39. Hrushesky WJ. Circadian timing of cancer chemotherapy. *Science*. 1985;228(4695):73–5.
40. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. *Annu Rev Pharmacol Toxicol*. 2007;47:593–628.
41. Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. Systems chronotherapeutics. *Pharmacol Rev*. 2017;69(2):161–99.
42. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and carbopol on drug release and bioadhesion of extended-release tablets. *J Pharm Sci*. 2003;92(3):605–13.
43. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and other natural polymers. *Int J Pharm*. 1992;78(1–3):43–8.
44. Dodou D, Breedveld P, Wieringa PA. Mucoadhesives in the gastrointestinal tract: revisiting the literature. *Eur J Pharm Biopharm*. 2005;60(1):1–16.
45. Andrews GP, Jones DS. Rheological characterization of bioadhesive systems. *J Pharm Pharmacol*. 2006;58(4):417–24.
46. Shaikh RP, Pillay V, Choonara YE, du Toit LC, Ndesendo VM. Gastroretentive drug delivery systems: a review. *Drug Deliv*. 2010;17(8):493–512.
47. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. *J Control Release*. 2006;111(1–2):1–18.
48. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. *AAPS PharmSciTech*. 2005;6(3):E372–90.
49. Whitehead L, Fell JT, Collett JH. Development of gastroretentive dosage forms. *Eur J Pharm Sci*. 1996;4(3):182–7.
50. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate-based microspheres for gastroretentive drug delivery. *AAPS PharmSciTech*. 2005;6(3):E372–80.
51. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Preparation of multiple-unit hollow microspheres (microballoons). *J Pharm Sci*. 1992;81(2):135–40.
52. Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. *Crit Rev Ther Drug Carrier Syst*. 2001;18(5):433–58.
53. Pozzi F, Furlani P, Gazzaniga A, Davis SS. The time clock system: a novel pulsatile drug delivery system. *J Control Release*. 1994;31(1):99–108.
54. Conte U, Maggi L. Modulation of drug release from Geomatrix systems. *Biomaterials*. 1996;17(9):889–96.
55. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles. *J Control Release*. 2001;70(1–2):1–20.
56. Müller RH, Keck CM. Challenges and solutions for the delivery of poorly soluble drugs. *Eur J Pharm Biopharm*. 2004;58(2):265–78.

57. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov*. 2005;4(2):145–60.
58. Jamróz W, Szafraniec J, Kurek M, Jachowicz R. 3D printing in pharmaceutical technology. *Pharm Res*. 2018;35(9):176.
59. Rasve VR, Chakraborty AK, Jadhav NY. A review: diabetes mellitus. World J Pharm Pharm Sci. 2021;10(4):961–974.
60. Goyanes A, Buanz AB, Basit AW, Gaisford S. Fused-filament 3D printing in pharmaceutics. *Adv Drug Deliv Rev*. 2014;73:78–89.
61. Kourentas A, Boudouvis AG, Goudeli E. Machine learning in drug delivery systems. *Adv Drug Deliv Rev*. 2020;156:225–36.
62. Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. *Annu Rev Pharmacol Toxicol*. 2014;54:339–61.
63. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic effects of circadian misalignment. *Proc Natl Acad Sci USA*. 2009;106(11):4453–8.